SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.

After Loomer targeted surgeon general nominee and Kennedy ally Casey Means, Means’s brother, Calley, suggested that Loomer’s ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Hansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with ...

Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular ...

President Trump's executive order to "identify and take appropriate action to correct past misconduct by the Federal Government related to censorship of protected speech" is good enough, DOJ tells ...

CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of ...

Evidence-based medicine "Boy Wonder" Dr. Vinay Prasad was fired as CBER Director after less than three months on the job.

US Food and Drug Administration Commissioner Marty Makary said he’s trying to persuade Vinay Prasad, the agency’s former head of gene therapy and vaccines, to return to the FDA after his abrupt ...

During his first term, Trump signed the “Right to Try” law, which allows terminally ill patients to seek treatments that haven’t been fully approved by the FDA, the AP reported.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the ...

Investing.com -- US Food and Drug Administration Commissioner Marty Makary is attempting to convince Vinay Prasad, who recently left his position as head of gene therapy and vaccines, to return to the ...